Holen Sie sich die Stockscreener-App
3.66
3.17%
-0.12
Handel nachbörslich:
3.66
Schlusskurs vom Vortag:
$3.78
Offen:
$3.81
24-Stunden-Volumen:
1.37M
Relative Volume:
0.80
Marktkapitalisierung:
$586.50M
Einnahmen:
$400.57M
Nettoeinkommen (Verlust:
$9.21M
KGV:
91.50
EPS:
0.04
Netto-Cashflow:
$146.36M
1W Leistung:
-7.58%
1M Leistung:
+3.68%
6M Leistung:
-46.33%
1J Leistung:
-70.39%
1-Tages-Spanne:
$3.58
$3.81
1-Wochen-Bereich:
$3.53
$3.895
52-Wochen-Spanne:
$3.06
$15.70
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Firmenname
Ironwood Pharmaceuticals Inc
Sektor
Telefon
617-621-7722
Adresse
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Vergleichen Sie IRWD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
3.66 | 586.50M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-08-08 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-09 | Eingeleitet | Jefferies | Buy |
| 2023-09-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-02 | Eingeleitet | CapitalOne | Overweight |
| 2022-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Eingeleitet | Northland Capital | Outperform |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Sell |
| 2018-05-09 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2017-07-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Eingeleitet | Wells Fargo | Outperform |
| 2017-04-07 | Bestätigt | Mizuho | Buy |
| 2017-02-22 | Bestätigt | Barclays | Equal Weight |
| 2016-11-04 | Bestätigt | Mizuho | Buy |
| 2016-10-24 | Bestätigt | Wedbush | Neutral |
| 2016-10-10 | Bestätigt | Mizuho | Buy |
| 2016-09-27 | Bestätigt | WallachBeth | Hold |
Alle ansehen
Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten
IRWD (Ironwood Pharmaceuticals) Cash From Discontinued Inve - GuruFocus.com
IRWD (Ironwood Pharmaceuticals) Net Income From Continuing Operations : $-3.1 Mil (TTM As of Sep. 2024) - GuruFocus.com
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 3.7%Should You Sell? - MarketBeat
Ironwood Pharmaceuticals (IRWD) Stock Dips Amidst Market Volatility - GuruFocus.com
Short Bowel Syndrome Pipeline Trends 2024: Clinical Trials, Analysis of Clinical Trials, Therapies, MOA, ROA, and Developments by DelveInsight | Zealand Pharma, Ironwood Pharma, Hanmi Pharma, Shire - Barchart
Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera - The Globe and Mail
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock Position Reduced by Harbor Capital Advisors Inc. - Defense World
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Down -69.69% This Year: What Is Going To Happen Next - Stocks Register
Zacks Research Issues Optimistic Estimate for IRWD Earnings - Defense World
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2 - MSN
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 8.7%What's Next? - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Sold by Principal Financial Group Inc. - Defense World
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $10.40 Consensus PT from Brokerages - Defense World
Ironwood Pharmaceuticals (IRWD) Stock Surges Amid Positive Analy - GuruFocus.com
Ironwood Pharmaceuticals (IRWD) Stock Drops Amid Industry Activi - GuruFocus.com
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 4.1%Here's Why - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Sees Significant Growth in Short Interest - Defense World
Analysts Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Price Target at $10.40 - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Sees Significant Increase in Short Interest - MarketBeat
Geode Capital Management LLC Trims Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Jane Street Group LLC Boosts Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Acquired by Jane Street Group LLC - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 5%Here's Why - MarketBeat
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too - Simply Wall St
State Street Corp Has $40.87 Million Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
State Street Corp Purchases 677,024 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - MarketBeat
Ironwood Pharmaceuticals shares surge on competitor's woes By Investing.com - Investing.com Canada
Here’s Why Brown Capital Management Small Company Fund Sold Ironwood Pharmaceuticals (IRWD) - Insider Monkey
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Stock Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Diabetic Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma, Takeda - The Globe and Mail
RBBN: 3 Penny Stocks to Watch for Big Gains in 2025 - StockNews.com
Fmr LLC Has $699,000 Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Up 4.6%Here's What Happened - MarketBeat
The Manufacturers Life Insurance Company Has $225,000 Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Ironwood Pharmaceuticals, Inc. Announces CFO Changes, Effective December 18, 2024 - Marketscreener.com
Ironwood Pharmaceuticals' SWOT analysis: apraglutide's promise lifts stock outlook - Investing.com
What is Zacks Research’s Forecast for IRWD FY2026 Earnings? - Defense World
Zacks Research Has Negative Outlook of IRWD FY2026 Earnings - MarketBeat
What Makes Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) One Of The Best Momentum Picks? - Stocks Register
Charles Schwab Investment Management Inc. Buys 364,841 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - MarketBeat
XBiotech (NASDAQ:XBIT) vs. Ironwood Pharmaceuticals (NASDAQ:IRWD) Critical Analysis - Defense World
High Growth Tech Stocks In The United States To Watch - Simply Wall St
Ironwood Pharmaceuticals, Inc. Announces Resignation of Sravan K. Emany as Senior Vice President and Chief Operating Officer, Effective December 18, 2024 - Marketscreener.com
216,707 Shares in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Purchased by Weiss Asset Management LP - MarketBeat
Hodges Capital Management Inc. Decreases Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Sets New 12-Month Low – Should You Sell? - Defense World
Ironwood Pharmaceuticals (NASDAQ:IRWD) Sets New 52-Week LowHere's Why - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Ironwood stock hits 52-week low at $3.25 amid market challenges - Investing.com
Ironwood Pharmaceuticals announces executive departure By Investing.com - Investing.com Canada
Ironwood Pharmaceuticals announces executive departure - Investing.com
Finanzdaten der Ironwood Pharmaceuticals Inc-Aktie (IRWD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.94%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):